543 results on '"Taxonera, Carlos"'
Search Results
102. Sa1955 Comparison of Four Assay Kits for Measuring Infliximab Trough Levels and Antibodies to Infliximab in Patients With Inflammatory Bowel Disease
103. Tu1925 Real-Life Experience With Golimumab in Ulcerative Colitis Patients According to Prior Anti-TNF Use
104. Sa1973 Loss of Anti-TNF Drugs Into Feces and Its Impact on Anti- TNF Serum Levels and Clinical Response in Crohn's Disease (CD) Patients
105. Sa1914 Long-Term Outcomes of a Cohort of Crohn's Disease Patients With Idiopathic Lymphopenia
106. P-044 Outcomes of Tuberculin Skin Test in Routine Screening for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Diseases
107. Physician Perspectives on Unresolved Issues in the Management of Ulcerative Colitis
108. Diagnostic Performance of the Simple Clinical Colitis Activity Index Self-Administered Online at Home by Patients With Ulcerative Colitis: CRONICA-UC Study
109. Outcomes of Medical and Surgical Therapy for Entero-urinary Fistulas in Crohn’s Disease
110. Adalimumab vs Azathioprine in the Prevention of Postoperative Crohn's Disease Recurrence. A GETECCU Randomised Trial.
111. Using of magnetic resonance enterography in the management of Crohn's disease of the small intestine: First year of experience
112. Adalimumab reversed a severe lymphopenia in a patient with Crohn's disease
113. FP484GRANULOCYTE APHERESIS IN REFRACTORY ULCERATIVE COLITIS: COMPARISON BETWEEN TWO THERAPEUTIC REGIMENS
114. Tu1107 Adalimumab Dose Escalation Is Effective for Managing Loss of Response in Ulcerative Colitis
115. Tu1293 Soluble TNF Serum Levels During the Induction Phase in Crohn's Disease Patients With Anti-TNF Treatment
116. Tu1291 Infliximab Serum Levels Do Not Predict Remission After the Induction Phase in Crohn's Disease Patients
117. 538 Correlation Between Adalimumab Serum Levels and Remission After the Induction Phase in Crohn's Disease Patients
118. Tu1292 Quantification of the Concentration of Antibodies Against Infliximab (IFX) in Human Serum Using a Pure Antibody As Calibrator
119. Tu1113 Endoscopic and Histologic Remission Correlation With Biomarkers in UC Patients Treated With Adalimumab
120. Response to Infliximab in Crohn’s Disease: Genetic Analysis Supporting Expression Profile
121. P-064 Adalimumab Achieves Mucosal and Histological Healing in Adult Patients With Moderate to Severe Ulcerative Colitis Naive to Anti-TNFα Treatment
122. Eosinophilic colitis: experience in a large tertiary hospital.
123. Tu1175 Incidence and Characteristics of Intestinal and Extraintestinal Cancers in Patients With Inflammatory Bowel Disease: A Population-Based Study
124. 210 Management and Course of Inflammatory Bowel Disease Patients With Associated Cancer
125. Mo1257 Outcomes of Surgical Treatment of Entero-Urinary Fistulas in Crohn's Disease
126. Tu1938 Identification of New Genetic Variants Related to Thiopurine-Induced Myelotoxicity in Inflammatory Bowel Disease (IBD) Patients With Normal Thiopurines-Methyltransferase (TPMT): A Genome-Wide Association Study
127. Sa1224 Usefulness of a Faecal Calprotectin Rapid Semiquantitative Test in Predicting Relapse in Patients With Ulcerative Colitis in Remission
128. Early Azathioprine Therapy Is No More Effective Than Placebo for Newly Diagnosed Crohn's Disease
129. Mo1343 Inflammatory Bowel Disease Unclassified in Real Practice: Prevalence, Clinical Course and Therapy Requirements
130. 951 Effectiveness of Anti-TNF Agents in the Treatment of Entero-Urinary Fistulas in Crohn's Disease
131. Su1752 Identification of New Genetic Variants Related to Thiopurine-Induced Myelotoxicity in Inflammatory Bowel Disease (IBD) Patients With Normal Thiopurines-Methyltransferase (TPMT): A Genome-Wide Association Study
132. Mo1383 Entero-Urinary Fistulas in Crohn's Disease: Prevalence and Clinical Manifestations
133. Using of magnetic resonance enterography in the management of Crohn's disease of the small intestine: First year of experience
134. Methotrexate in inflammatory bowel disease
135. Sa1888 Need for Infliximab Dose Intensification in Patients With Crohns Disease and Ulcerative Colitis
136. Sa1933 Safety of Immunomodulators and Anti-TNF Drugs for the Treatment of Inflammatory Bowel Disease (IBD) During Pregnancy
137. Mo1712 How Frequent are Conversions of Tuberculosis (TBC) Screening Tests Among Inflammatory Bowel Disease (IBD) Patients Under Anti-TNF Treatment?
138. Sa1902 Short- and Long-Term Outcomes of Infliximab Dose Intensification in Patients With Ulcerative Colitis
139. 119 - FACTORES PREDICTIVOS DE RESPUESTA A FILGOTINIB EN COLITIS ULCEROSA: ANÁLISIS POST HOCDEL ESTUDIO SELECTION
140. Mucosal healing for predicting clinical outcome in patients with ulcerative colitis using thiopurines in monotherapy
141. Likelihood of detecting latent tuberculosis infection before and during infliximab therapy
142. Differential association of two PTPN22 coding variants with Crohnʼs disease and ulcerative colitis
143. Analysis of the influence of two CD24 genetic variants in Crohn's disease and ulcerative colitis
144. TLR9 and IL23R Genetic Interaction Modulates Crohn'S Disease Susceptibility
145. Safety of Immunomodulators and Anti-TNF Drugs for the Treatment of Inflammatory Bowel Disease (IBD) During Pregnancy
146. Decreasing Rates of Hospital Admissions for Inflammatory Bowel Disease Between 2000 and 2009
147. Epidemiological Study of Perianal Fistulas in Patients With Crohn's Disease
148. Association of Susceptibility Variants With Non-Perianal Crohn's Disease-Related Surgery
149. Early Use of Azathioprine Has a Steroid Sparing Effect on Recently Diagnosed Crohn's Disease Patients
150. Serial Tuberculin Skin Tests to Detect Latent Tuberculosis in Inflammatory Bowel Disease Patients Receiving Infliximab Therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.